Skowronek J, Piotrowski T, Młynarczyk W, Ramlau R
Department of Brachytherapy, Greatpoland Cancer Center, 61-866 Poznan, Poland.
Neoplasma. 2004;51(4):313-8.
The purpose of this study was to determine the benefit of high dose rate endotracheal brachytherapy as an exclusive palliative treatment of obstructive tracheal cancer. Thirty-five patients with advanced tracheal carcinoma were treated between May 1999 and March 2001 in Greatpoland Cancer Center. They were qualified for brachytherapy due to life-threatening situations. Fourteen patients were irradiated using three fractions 7.5 Gy each one every week, six patients received three fractions 10 Gy each one every week and fifteen patients received one fraction of 10 Gy. Survival time was compared with chosen clinical factors (age, sex, Karnofsky status, tumor location, lymph nodes involvement and percent of obturation) and prescribed dose. The median survival (Kaplan-Meier) for all patients was 6.6 months. Patients with an endoscopically controlled complete remission 4 weeks after the treatment had a significantly better survival in comparison to patients with a partial remission or no change of tumor size (p=0.0003). Univariate analysis revealed significant difference between patients with Karnofsky score equal with 60 or lower (28/35, 80%) and higher than 60 (7/35, 20.0%) (p=0.005). Difference between the grade of tumor obturation (more than 60% of tracheal lumen (27/35, 77.1%), 60% or lower (8/35, 22.9%) was found in univariate analysis (p=0.04). In multivariate analysis statistically important prognostic factor for survival was Karnofsky score (p=0.04). Statistical analysis revealed no differences in survival according to sex and age (p=0.43 for age, p=0.19 for sex), tumor localization (p=0.13), lymph node involvement (p=0.48) or fractionation scheme (p=0.62). Exclusive HDR brachytherapy of advanced tracheal carcinoma was a safe palliative method of treatment and caused in many patients prolonged survival and improved quality of life. Most important prognostic factor for survival, confirmed in both univariate and multivariate analysis, was Karnofsky score.
本研究的目的是确定高剂量率气管内近距离放射疗法作为阻塞性气管癌唯一姑息治疗方法的益处。1999年5月至2001年3月期间,在大波兰癌症中心对35例晚期气管癌患者进行了治疗。由于危及生命的情况,他们符合近距离放射治疗的条件。14例患者每周接受3次照射,每次7.5 Gy;6例患者每周接受3次照射,每次10 Gy;15例患者接受1次10 Gy的照射。将生存时间与选定的临床因素(年龄、性别、卡诺夫斯基状态、肿瘤位置、淋巴结受累情况和阻塞百分比)以及规定剂量进行比较。所有患者的中位生存时间(Kaplan-Meier法)为6.6个月。与部分缓解或肿瘤大小无变化的患者相比,治疗后4周内镜检查显示完全缓解的患者生存情况明显更好(p = 0.0003)。单因素分析显示,卡诺夫斯基评分等于或低于60分的患者(28/35,80%)与高于60分的患者(7/35,20.0%)之间存在显著差异(p = 0.005)。单因素分析发现肿瘤阻塞程度(气管腔超过60%(27/35,77.1%),60%或更低(8/35,22.9%))之间存在差异(p = 0.04)。多因素分析显示,卡诺夫斯基评分是生存的重要预后因素(p = 0.04)。统计分析显示,根据性别和年龄(年龄p = 0.43,性别p = 0.19)、肿瘤定位(p = 0.13)、淋巴结受累情况(p = 0.48)或分割方案(p = 0.62),生存情况无差异。晚期气管癌的单纯高剂量率近距离放射疗法是一种安全的姑息治疗方法,可使许多患者延长生存期并提高生活质量。单因素和多因素分析均证实,生存的最重要预后因素是卡诺夫斯基评分。